spacer
home > epc > Winter 2004
PUBLICATIONS

European Pharmaceutical Contractor

epc
Winter 2004
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EPC provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of EPC
   
Text
PDF
bullet
introduction
In her Editor's Letter, Julia Lloyd-Parks reviews the latest offerings in this our Winter issue  
download pdf
bullet
Marketplace & Business
In the first instalment of a regular series looking at the hottest issues in our industry as they happen, BearingPoint's Craig Wylie, Senior Manager, Life Sciences, and Hitesh A Anklesaria, Security Solutions Developer, take us through A SAFE Development - Secure Identity Evolves in Pharma  
download pdf
Shortcomings in the management of risk can carry immense costs for pharmaceutical companies. Chris Buxton, Partner, and Evelyne Lemaire, Director at PricewaterhouseCoopers, thankfully are on board to provide a Risk Strategy: Managing Inwards and Communicating Outwards
 
download pdf
Robin Cammish, CEO of the QP Group, contends that procurement and supply represents a major opportunity for post-merger synergy and major savings, in Understanding Pharmaceutical Mergers and Acquisitions  
download pdf
Translating for the Pharma Industry: An Invisible Mission - Roberto Ganzerli, President and CEO of Arancho, discusses the complex, invaluable relationship between language service providers and pharmaceutical companies  
download pdf
In the pursuit of best practice as a way of life in the pharma sector, Glenn Van Dael, Manager in the Life Science Consulting Group at First Consulting Group, presents The Application of Change and Content Management to the Clinical Trials Process  
download pdf
bullet
Clinical Trials: Patient Recruitment & Retention
Tom Ruane, Director of Patient Recruitment at Quintiles, offers his expertise in the search for efficient and streamlined Patient Recruitment: Integrated Services Provide the Key to Success  
download pdf
Don't Leave Patient Recruitment and Retention to Chance, exclaims John Dent, Patient Recruitment Director at (Pi) Patient interaction, as he presents us with three steps that, if implemented quickly, will certainly improve results  
download pdf
Emma Sergeant, President of Fast4wD Ogilvy, Clinical Trial Practice Worldwide, Nicky Sturt, Communications Director, and Gaynor Anders, Communications Director at Fast4wD Ogilvy Europe, mull over The Challenge of Participant Retention in Clinical Trials  
download pdf
bullet
Clinical Trials
With sponsors spending more money on larger trials for their drug candidates in the hope of weeding out drugs destined to fail before they enter expensive Phase II and III trials, Dries De Pauw, Global Business Manager, Clinical Research, at SGS Life Science Services, asserts the need for Putting Phase I in the Spotlight  
download pdf
Richmond Pharmacology brings together pharmaceutical industry representatives and leading cardiology opinion leaders to discuss The Definitive QTc Study - Notes from a Workshop  
download pdf
bullet
Legal & Regulatory
The Challenges of Implementing the European Clinical Trials Directive in the UK are reviewed by the MHRA's Brian Davis, Chairman of the Project Team responsible for implementing the Directive  
download pdf
Animal research currently provides essential guidance on how a medicine will act in the body, enabling scientists to bridge the gap between theory and practice. Dr Philip Wright, Director of Science & Technology at the ABPI, considers A Stark Choice: Stop Animal Research or Stop Developing New Medicines  
download pdf
Ben Rapinoja, Attorney and Hannu Jarvinen, Associate Lawyer at Attorneys at law Borenius & Kemppinen Ltd, assess the intricacies of Commercialising Academic Research - A Finnish Perspective  
download pdf
bullet
IT Solutions
The pharmaceutical industry has been relatively absent in the dialogue about mainstreaming telecare - its voice now needs to be heard, argues Professor James Barlow, Chair in Technology and Innovation Management, Tanaka Business School, at Imperial College London, in Emerging Telecare Services - Implications for Pharmaceutical Companies  
download pdf
In Electronic Patient Reported Outcomes - Methods that Put Paper out to Dry and Quality First - Christine Lys, Director of Business Development at etrials Worldwide, examines why, despite serious technological advances, pharmaceutical companies have been slow to adopt and use eClinical tools  
download pdf
bullet
Drug Discovery & Delivery
New Vaccines - Opportunities and Challenges? Dr V K Vinayak, Advisor/Consultant - New Initiative (R&D) at Panacea Biotech Ltd, gives us his perspective on the developments in this cornerstone of medical science  
download pdf
Dr Andreas Herrmann, Managing Director of Celonic, reflects on the steps to be considered in order to achieve a reliable process for drug production, in Process Development of Pharmaceutical Proteins: The Opportunities & Pitfalls  
download pdf
New research shows that plants contain many novel carbohydrate-like molecules with valuable therapeutic properties that have been missed in the past. In A New Generation of Carbohydrate Mimic Drugs, Robert Nash, Research Director of Molecular Nature Limited, puts the case for herbal medicines  
download pdf
bullet
Therapeutic Innovation
In Measuring Treatment Efficacy in Fronto-temporal Dementia, Dr Barbara Collins, Director of Global Product Development at PRA International, laments the lack of an approved treatment for 'non-Alzheimer' dementia, and deliberates design considerations for future clinical trials  
download pdf
Dr Darren Poinasamy, Business Development Executive at Chiltern International, considers The Future of Drug Delivery in Diabetes - a disease that affects 177 million people worldwide and, more worryingly still, is predicted to reach 300 million by 2025  
download pdf
Whilst there are a number of novel products in the pipeline, history has shown that the attrition rate of drugs in the respiratory marketplace is high. Shaun Falkingbridge, Respiratory Analyst at Datamonitor, evaluates the potential of The Respiratory Market: A Wealth of Opportunities  
download pdf
bullet
Labs & LIMS
In SMARTer LIMS - Establishing Global Systems for the Real World, John Boother, Managing Director of Autoscribe Limited, challenges us to revolutionise the working environment within pharma laboratories  
download pdf
Whilst the principles and benefits of measurement uncertainty estimation are well-recognised by the bioanalytical community, few disciplines implement a full measurement uncertainty budget with their results. Dr Malcolm Burns, Biostatistician, Bioanalytical Innovation Team at LGC, examines Bioanalytical Measurements - Attitudes in an Uncertain World  
download pdf
bullet
LABS & Logistics
Natalie Roy, Product Manager for Cold Chain Solutions at Gemini Data Loggers (UK) Ltd, borrows the concept of an integrated system to achieve a Joined-up Cold Chain: Meeting Stringent Requirements  
download pdf
In Successful Supply Chain Planning in Pharmaceuticals, Matthew Spooner and Eugene Van Dijk, Senior Consultants at World Class International, try to keep us on the side of efficiency  
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZenecaís (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZenecaís state-of-the-art HTS facility.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developerís mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

Industry Events

LogiPharma Europe 2018

10-12 April 2018, Montreux Music & Convention Centre

Now in itís 18th successful year, LogiPharma is the largest global end-to-end supply chain event for pharma supply chain leaders, their teams and service partners.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement